According to a Reuters report, the CDSCO has issued a warning after a sample of Abhayrab—a rabies vaccine produced by Indian Immunologicals that accounts for 40% of the local market—did not pass a quality check. The drug regulatory body has instructed officials to keep a close watch on batch number KE25012 of the vaccine. Concerns regarding counterfeit products were raised after the sample showed inconsistencies in its licensing information, cap color, artwork, and labeling.

by shortkt.com✓

2 hours ago